Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rh-endostatin [Endostar] Injection plus paclitaxel and carboplatin therapy for non-small-cell lung cancer: Randomized, double-blind, placebo-controlled, multicentre study.

Trial Profile

Rh-endostatin [Endostar] Injection plus paclitaxel and carboplatin therapy for non-small-cell lung cancer: Randomized, double-blind, placebo-controlled, multicentre study.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Endostatin (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Sponsors Shandong Simcere Medgenn Bio-Pharmaceutical
  • Most Recent Events

    • 05 Jun 2012 Biomarker analysis presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 28 Apr 2011 Primary endpoint 'Progression-free-survival' has not been met, based on results published in the Journal of Thoracic Oncology.
    • 28 Apr 2011 Results published in the Journal of Thoracic Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top